Cargando…
Imatinib may be ABL to improve anti-angiogenic therapy
We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degene...
Autores principales: | Raimondi, Claudio, Fantin, Alessandro, Ruhrberg, Christiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905228/ https://www.ncbi.nlm.nih.gov/pubmed/27308396 http://dx.doi.org/10.4161/23723548.2014.968034 |
Ejemplares similares
-
Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1–dependent ABL1 activation in endothelial cells
por: Raimondi, Claudio, et al.
Publicado: (2014) -
NRP1 function and targeting in neurovascular development and eye disease
por: Raimondi, Claudio, et al.
Publicado: (2016) -
VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation
por: Fantin, Alessandro, et al.
Publicado: (2017) -
NRP1 Regulates CDC42 Activation to Promote Filopodia Formation in Endothelial Tip Cells
por: Fantin, Alessandro, et al.
Publicado: (2015) -
The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)